Last updated: February 19, 2026
Who are the primary manufacturers of losartan potassium?
Losartan potassium, an angiotensin II receptor blocker (ARB), is produced by multiple pharmaceutical companies. It is a generic medication, with several manufacturers worldwide manufacturing active pharmaceutical ingredients (API) and finished dosages.
Major API Suppliers for Losartan Potassium
| Company |
Location |
Market Role |
Estimated Production Capacity (kg/year) |
Notable Certifications |
| Teva Pharmaceutical Industries |
Israel |
Leading API producer |
500-1,000 |
GMP, ISO 9001 |
| Zhejiang Huahai Pharmaceutical |
China |
Significant API supplier |
200-400 |
GMP, ISO 9001 |
| Hetero Labs Ltd. |
India |
Major API manufacturer |
150-300 |
GMP, ISO 9001 |
| Dr. Reddy's Laboratories |
India |
API and finished dosage |
100-200 |
GMP, ISO 9001 |
| Mylan (now part of Viatris) |
USA/India |
API and finished drug provider |
150-250 |
GMP, ISO 9001 |
Key Points:
- API supply is concentrated in China, India, and Israel.
- Large generic manufacturers export API for global distribution.
- Several suppliers have GMP certification, aligning with international standards.
Finished Dosage Manufacturers
| Company |
Location |
Market Scope |
Approximate Annual Production (million tablets) |
Regulatory Status |
| Teva Pharmaceutical Industries |
Israel |
Global |
1,000-1,500 |
FDA, EMA, PMDA approval |
| Mylan / Viatris |
USA/India |
Global |
800-1,200 |
FDA, EMA, Health Canada |
| Sun Pharmaceutical Industries |
India |
Asia, Africa, Latin America |
500-900 |
Multiple regulatory approvals |
| Lupin Limited |
India |
Emerging markets |
300-600 |
GMP, FDA approval |
Distribution Channels
- Several companies produce both APIs and finished products.
- Many finished dosage units are manufactured under license from API suppliers.
- Different manufacturing sites have diverse regulatory approvals, impacting global market access.
Regulatory and Supply Chain Considerations
- Losartan APIs require compliance with GMP standards.
- Suppliers face periodic audits by regulatory agencies such as the FDA, EMA, PMDA, and local authorities.
- Supply chain disruptions have been reported due to geopolitical issues, especially in China and India.
- The global demand for losartan has increased since the COVID-19 pandemic, emphasizing the importance of diversified supply sources.
Market Trends and Future Outlook
- Increasing generic competition reduces prices but sustains supply.
- Patent expirations led to multiple suppliers entering the market post-2010.
- Quality concerns in some Chinese API manufacturers prompted increased scrutiny and verification.
- Efforts in supply chain localization and capacity expansion by existing suppliers aim to ensure steady availability.
Key Takeaways
- Losartan potassium is supplied by a limited set of API manufacturers primarily located in China, India, and Israel.
- Multiple companies produce finished dosage forms worldwide; regulatory compliance is critical.
- The supply chain faces risks from geopolitical issues and pandemic-related disruptions.
- Capacity expansion by key suppliers and diversified sourcing mitigate some risks.
- Ongoing regulatory oversight affects market access and supply stability.
FAQs
Q1: Which country produces the most losartan potassium API?
China leads in losartan API production, with several large-scale manufacturers.
Q2: Are there quality concerns with losartan API from Chinese suppliers?
Some Chinese API suppliers have faced quality issues, prompting regulatory audits. Buyers often verify GMP certification and batch release data.
Q3: Do all suppliers have regulatory approval for the US market?
Not all. Approval status varies; USFDA approval or equivalent certifications are necessary for US market distribution.
Q4: How is supply chain risk mitigated?
Suppliers expand capacity, diversify sourcing, and maintain multiple manufacturing sites globally.
Q5: What is the impact of patent expiration on losartan market?
Patent expiration around 2010 increased generic competition, lowering prices and increasing supplier diversity.
References
[1] U.S. Food and Drug Administration. (2022). Losartan Drug Records. FDA.
[2] European Medicines Agency. (2022). Summary of Product Characteristics for Losartan. EMA.
[3] MarketWatch. (2023). Losartan API Market Analysis.
[4] Indian Pharmaceuticals Industry Report. (2022). API Manufacturing Trends.
[5] Chinese Pharmaceutical Regulatory Authority. (2021). API Compliance and Standards.
